mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Keytruda (pembrolizumab) was granted Priority Medicines scheme designation by the European Medicines Agency for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
